Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacodynamics

11 evidence topics · 9 sources

Thorough QT study of DT120 ODT: treatment-emergent adverse events
MeasurePhase 1 TQT study, DT120 ODT (n = 58)
Any TEAE“57 (98.3)”
TEAE leading to treatment withdrawal“0”
Mild“27 (46.6)”
Moderate“27 (46.6)”
Severe“3 (5.2)”
Any related TEAE“57 (98.3)”
Dose-response of subjective effects and ceiling at 100 µg in healthy participants